SCHEMBL848769

SCHEMBL848769

CC(=O)C(=[N+]=[N-])P(=O)(O)O

nearest known ligand 0.32

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 1/20 0.31
MMP3 P08254 1/20 0.31
MMP8 P22894 1/20 0.31
TSHR P16473 1/20 0.30
THPO P40225 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11951301 0.79 TSHR (0.30) TSHRTHPO
SCHEMBL5037124 0.77
SCHEMBL187536 0.76
SCHEMBL17772 0.73
SCHEMBL102146 0.73 MMP1 (0.33) MMP2MMP8
SCHEMBL5037125 0.73 MMP1 (0.33) MMP2MMP3MMP8
SCHEMBL3538407 0.73
SCHEMBL17106814 0.72 MMP1 (0.31) MMP2MMP3MMP8
SCHEMBL2110311 0.70 MMP1 (0.36) MMP2MMP3MMP8TSHR
SCHEMBL20270690 0.70

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1262 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220177647-A1 FLUOROPOLYETHER GROUP-CONTAINING COMPOUND DAIKIN INDUSTRIES, LTD. (JP) 2022-06-09 US claimed
CN-108569969-A A kind of synthetic method of 3-aminophenylacetylene 西安格瑞德化工新材料有限公司 2018-09-25 CN claimed
WO-2014001527-A2 LIPID ANALYSIS Rheinische Friedrich-Wilhelms-Universität Bonn (DE) 2014-01-03 WO claimed
US-20240336594-A1 SIX-MEMBERED ARYL OR HETEROARYL AMIDES, AND COMPOSITION AND USE THEREOF BETTA PHARMACEUTICALS CO., LTD (CN) 2024-10-10 US disclosed
US-20240239777-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2024-07-18 US disclosed
WO-2024150815-A1 CEREBLON E3 LIGASE BINDING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PRODUCTION METHOD THEREFOR 田辺三菱製薬株式会社 2024-07-18 WO disclosed
CN-118324846-A Bufogargarizin A preparation method 南方科技大学 2024-07-12 CN disclosed
US-20240226094-A1 ALPHA PROTEIN KINASE 1 INHIBITORS FOR USE IN TREATING KAWASAKI DISEASE XU, Cong (CN) 2024-07-11 US disclosed
US-20240228488-A1 HETEROARYL INHIBITORS OF PLASMA KALLIKREIN TAKEDA PHARMACEUTICALS CO (JP) 2024-07-11 US disclosed
EP-4396187-A1 NAPHTHYRIDINE COMPOUNDS AS INHIBITORS OF KRAS Incyte Corporation (US) 2024-07-10 EP disclosed
WO-2024140704-A1 PYRIDAZINE FUSED ARYL RING COMPOUND AND USE THEREOF 正大天晴药业集团股份有限公司 2024-07-04 WO disclosed
US-6552239-B1 Reacting ketophosphonate with diazo-transfer reagent generating a ketodiazophosphonate which is reacted with cyclopropanecarboxaldehyde MERCK & CO., INC. 2003-04-22 US disclosed
WO-2003031434-A1 COMPOUNDS AND METHODS SMITH KLINE BEECHAM CORPORATION (US) 2003-04-17 WO disclosed
EP-1274424-A1 COMPOUNDS AND METHODS SMITHKLINE BEECHAM CORPORATION (US) 2003-01-15 EP disclosed
US-20020156273-A1 Streptogramin derivatives, their preparation and compositions which contain them NOVEXEL (FR) 2002-10-24 US disclosed
WO-2002081415-A2 METHOD FOR INHIBITING METAP2 SMITHKLINE BEECHAM CORPORATION (US) 2002-10-17 WO disclosed
US-6458830-B1 THE COMPOUNDS ARE OF PARTICULAR USE IN THE TREATMENT OR PREVENTION OF DEPRESSION, ANXIETY, PAIN, INFLAMMATION, MIGRAINE, EMESIS AND POSTHERPETIC NEURALGIA. MERCK SHARP & DOHME LTD. 2002-10-01 US disclosed
EP-1165540-A1 TETRAHYDROPYRAN DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS MERCK SHARP & DOHME LTD. (GB) 2002-01-02 EP disclosed
WO-2001078723-A1 COMPOUNDS AND METHODS SMITHKLINE BEECHAM CORPORATION (US) 2001-10-25 WO disclosed
WO-2000056727-A1 TETRAHYDROPYRAN DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS MERCK SHARP & DOHME LIMITED (GB) 2000-09-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240226094-A1 ALPHA PROTEIN KINASE 1 INHIBITORS FOR USE IN TREATING KAWASAKI DISEASE PHKA1, PHKA2, PHKG1 MMP2 1725/4885MMP3 1691/4885MMP8 1812/4885
US-20240336594-A1 SIX-MEMBERED ARYL OR HETEROARYL AMIDES, AND COMPOSITION AND USE THEREOF MALT1, CYP51A1, BCR MMP2 3864/4885MMP3 3559/4885MMP8 4389/4885
US-20240228488-A1 HETEROARYL INHIBITORS OF PLASMA KALLIKREIN KLKB1, KLK5, KLK1 MMP2 244/4885MMP3 271/4885MMP8 301/4885
US-20020156273-A1 Streptogramin derivatives, their preparation and compositions which contain them MRPL21, SRI, STS MMP2 379/4885MMP3 672/4885MMP8 939/4885
US-20240239777-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 MMP2 1393/4885MMP3 831/4885MMP8 901/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.